A recent study reported that bempedoic acid, an FDA-approved ACLY inhibitor, alleviates NASH and improves glycemic control primarily by suppressing lipogenesis and inflammation (20). Here, ACLY is linked to metabolic dysfunction-associated steatohepatitis.